Eybna and CannaSoul, Top Cannabis R&D Firms, Join Forces to Prove a Proprietary Terpene Formulation for Treating Viral Infections via Modulation of Cytokine Storm

May 13, 2020

Eybna and CannaSoul, Top Cannabis R&D Firms, Join Forces to Prove a Proprietary Terpene Formulation for Treating Viral Infections via Modulation of Cytokine Storm

Posted by Brent Ellman in category: biotech/medical

TEL AVIV, Israel, April 22, 2020 /PRNewswire/ — Prof. Dedi (David) Meiri, Chairman and CSO of CannaSoul and Nadav Eyal, Co-founder and CEO of Eybna Technologies Ltd, announced today the companies have jointly engaged in a mutual assays of CannaSoul’s (through its Myplant-Bio subsidiary) Cytokine Storm Assay and Eybna’s Novel NT-VRL™ formulation dedicated for treatment and prevention of viral infections — specifically for high-risk populations and treatment of actively ill patients.